FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / News / Read News


Truist Securities Bolsters Biotech Investment Banking Team

September 24, 2021, 07:50 AM

Truist Securities announced that Lorenzo Paoletti has joined the firm as managing director to lead the Biotech investment banking team. Working together with Michael Allwin, who joined Truist Securities in August as managing director, these experienced professionals bolster and strengthen the firm’s Biotech investment banking capabilities and will focus on clients including public and private biotechs and venture firms that seed new companies with promising break-through science.
Paoletti and Allwin both previously covered the Biotech sector at Credit Suisse. They will be based in New York City.  

“Over the past two years, we’ve been building a leading Life Sciences industry practice, and Lorenzo’s and Michael’s extensive experience helping Biotech companies achieve their capital formation goals and strategic objectives will benefit our clients as well as our Biotech investment banking team,” said Tom Hackett, president and chief operating officer of Truist Securities.  
Hackett noted other recent team additions as examples of the firm’s expanded capabilities to deliver innovative solutions and creative advice to Life Sciences and Biotech clients, including investment banker Pete Cataldo, who now leads MedTech investment banking.
During that time, the firm also added healthcare sales specialist Gregg Genova and built out its extensive Life Sciences research team, including the addition of Robyn Karnauskas.  
Paoletti has more than 14 years of experience in investment banking. Prior to joining Truist, Paoletti helped spearhead the Biotech investment banking effort at Credit Suisse. Before Credit Suisse, Paoletti was a managing director covering the Biotech sector on the investment banking team at RBC Capital Markets. Paoletti holds a bachelor’s degree with high honors in economics from Butler University and an MBA from the New York University Stern School of Business.
Allwin was previously a senior member of the Life Sciences investment banking team at Credit Suisse focused on coverage in Biotech. Prior to Credit Suisse, he was a senior member of the equity capital markets division of RBC Capital Marlets where he helped lead origination and execution of equity and equity-linked transactions in the Biotech sector. Allwin received his bachelor’s degree in political science and economics from Bucknell University.

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.